{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:03:14Z","timestamp":1775469794084,"version":"3.50.1"},"reference-count":19,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Hepatitis B virus (HBV) reactivation in oncology patients receiving chemotherapy can cause severe hepatitis, including hepatic failure and death. Universal HBV screening before chemotherapy initiation can reduce HBV-related morbidity; however, screening practices vary widely, and guideline recommendations continue to evolve. Objective: The aim of this study was to evaluate the implementation of universal HBV screening in oncology patients and its effectiveness in identifying active infection, prior exposure, and individuals at risk for HBV reactivation. Methods: We implemented universal HBV screening at Rambam Health Care Campus in January 2018 for all patients initiating chemotherapy. This retrospective cohort study analyzed 1614 oncology patients who underwent chemotherapy between January 2018 and April 2024. Screening included testing for HBsAg, anti-HBc, and anti-HBs serology. HBV DNA testing was performed in patients with positive HBsAg and\/or anti-HBc serology. Patients with known HBsAg positivity or those already receiving antiviral therapy were excluded. Results: Of the screened patients, 16 (1.0%) were HBsAg-positive, and 134 (8.3%) were HBsAg-negative\/anti-HBc-positive. Detectable HBV DNA was identified in four patients (3%) within the latter group. One additional patient was classified as high risk for HBV reactivation based on the planned chemotherapy regimen. Overall, 21 patients met criteria for prophylactic antiviral therapy; however, prophylaxis was administered to only 17 patients. Notably, when applying the 2015 ASCO guidelines, only a single patient within the subgroup of HBsAg-negative, anti-HBc-positive, and HBV DNA-negative patients would have qualified for HBV serologic screening based on chemotherapy-related risk alone. Conclusions: Universal HBV screening prior to chemotherapy enables the identification of patients with active or prior HBV infection who would not have been detected using risk-based screening strategies alone. Our findings further support the implementation of universal HBV screening in oncology settings to prevent HBV reactivation and its potentially severe consequences.<\/jats:p>","DOI":"10.3390\/jcm15072757","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T08:58:48Z","timestamp":1775465928000},"page":"2757","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Impact of Routine HBV Screening in Oncologic Patients Prior to Chemotherapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Husam","family":"Abu Sini","sequence":"first","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel"},{"name":"Division of Oncology, Rambam Health Care Campus, Haifa 3109601, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5509-3937","authenticated-orcid":false,"given":"Natali","family":"Shirron","sequence":"additional","affiliation":[{"name":"Division of Oncology, Rambam Health Care Campus, Haifa 3109601, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Litvak","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel"},{"name":"Division of Oncology, Rambam Health Care Campus, Haifa 3109601, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4016-9252","authenticated-orcid":false,"given":"Roni","family":"Nasser","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel"},{"name":"Liver Unit, Rambam Health Care Campus, Haifa 3109601, Israel"},{"name":"Department of Gastroenterology, Rambam Health Care Campus, Haifa 3109601, Israel"},{"name":"Internal Medicine B, Rambam Health Care Campus, Haifa 3109601, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5428-7180","authenticated-orcid":false,"given":"Fadi","family":"Abu Baker","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel"},{"name":"Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Hadera 38100, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-118X","authenticated-orcid":false,"given":"Rawi","family":"Hazzan","sequence":"additional","affiliation":[{"name":"Clalit Health Services, Afula 1834111, Israel"},{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nissim","family":"Haim","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel"},{"name":"Division of Oncology, Rambam Health Care Campus, Haifa 3109601, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Saadi","sequence":"additional","affiliation":[{"name":"Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel"},{"name":"Liver Unit, Rambam Health Care Campus, Haifa 3109601, Israel"},{"name":"Department of Gastroenterology, Rambam Health Care Campus, Haifa 3109601, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"m2200","DOI":"10.1136\/bmj.m2200","article-title":"Hepatitis B virus persistence and reactivation","volume":"370","author":"Shi","year":"2020","journal-title":"BMJ"},{"key":"ref_2","unstructured":"Ministry of Health, Israel (2024, October 01). Hepatitis B Vaccination Program, Available online: https:\/\/www.health.gov.il."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1017\/S0022172400038778","article-title":"The epidemiology of infectious hepatitis in Israel","volume":"59","author":"Davies","year":"1961","journal-title":"J. Hyg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/13557858.2022.2040957","article-title":"The impact of ethnicity on chronic hepatitis B infection course and outcome: Big data analysis from Israel","volume":"28","author":"Green","year":"2023","journal-title":"Ethn. Health"},{"key":"ref_5","first-page":"E3","article-title":"Epidemiology of hepatitis B virus infection in the Asia-Pacific region","volume":"15","author":"Chen","year":"2000","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: Risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_8","unstructured":"Naggie, S., Sulkowski, M.S., Rodriguez-Baez, N., Chen, J., Murad, M.H., Mohammad, K.S., Terrault, N.A., and for the AASLD\/IDSA Practice Guideline Panel (2025). AASLD\/IDSA practice guideline on treatment of chronic hepatitis B. Hepatology, in press."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL) (2017). EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","article-title":"ASCO provisional clinical opinion: Chronic hepatitis B virus screening in patients receiving cytotoxic chemotherapy","volume":"28","author":"Artz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2015.61.3745","article-title":"Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update","volume":"33","author":"Hwang","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","article-title":"Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices","volume":"5","author":"Ramsey","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1200\/JCO.2017.75.6387","article-title":"Models to predict hepatitis B virus infection among patients with cancer undergoing systemic anticancer therapy: A prospective cohort study","volume":"36","author":"Hwang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_14","first-page":"703","article-title":"Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg?","volume":"61","author":"Lok","year":"2014","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Holtkamp, C., Fiedler, M., Dittmer, U., and Anastasiou, O.E. (2022). The Course of Anti-HBc Antibodies Over Time in Immunocompromised Hosts. Vaccines, 10.","DOI":"10.3390\/vaccines10020137"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR. Recomm. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00097","article-title":"Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy","volume":"3","author":"Hwang","year":"2019","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2011.35.1635","article-title":"Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors","volume":"29","author":"Day","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JGO.2015.001669","article-title":"Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors","volume":"2","author":"Tan","year":"2016","journal-title":"J. Glob. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2757\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:06:15Z","timestamp":1775466375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15072757"],"URL":"https:\/\/doi.org\/10.3390\/jcm15072757","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}